6365822149112

Rachel E. Rau, MD, pediatric oncologist, Seattle Children’s Hospital, University of Washington, discusses results from the phase 3 Children’s Oncology Group Study AALL1731 (NCT03914625), which showed that adding 

blinatumomab (Blincyto) to chemotherapy improved 3-year disease-free survival rates

 in newly diagnosed, standard risk pediatric B-cell acute lymphoblastic leukemia.  Rau and colleagues shared these results in a presentation at the 

Videos

 Rachel E. Rau, MD, discusses findings that show blinatumomab plus chemotherapy improves DFS in newly diagnosed B-ALL.

Rachel E. Rau, MD

Articles

Dr Rau on Treatment With Blinatumomab and Chemo in Newly Diagnosed Pediatric B-ALL